Annovis Bio prices $15M public offering of 7.9M shares and warrants

Annovis Bio, Inc.

Offering of 7,895,000 shares and warrants for 7,105,500 shares at combined price $1.90.
Gross proceeds of ~$15M; expected closing May 21, 2026.
Warrants exercisable at $2.25 per share, six-year term from issuance.
Net proceeds for clinical development of buntanetap in Alzheimer's and Parkinson's and working capital.
Canaccord Genuity acting as sole bookrunner.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Annovis Bio, Inc. entered into Underwriting Agreement with Canaccord Genuity LLC valued at approximately $15 million (effective 2026-05-20).

Action: entry
Agreement: underwriting
Counterparty: Canaccord Genuity LLC
Value: approximately $15 million
Effective: 2026-05-20

Exact text from the filing

On May 20, 2026, Annovis Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”), dated as of May 20, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”) (i) an aggregate of 7,895,000 shares of common stock (the “Shares”), $0.0001 par value per share (the “Common Stock”), of the Company and (ii) accompanying common stock warrants to purchase up to an aggregate of 7,105,500 shares of Common Stock (the “Warrants” and the shares of Common Stock issuable upon exercise of the Warrants, the “Warrant Shares”).

View on SEC.gov

Browse all material agreements →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-064514

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.